Global Interventional Oncology Ablation Market, by Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation) by Indication (Liver Cancer, Kidney Cancer, Lung Cancer, Other Indications), By End-Use (Hospitals, Ambulatory Surgical Centers, Other End-Uses), and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Interventional Oncology Ablation Market Overview

The global interventional oncology ablation market is projected to reach a USD 1,035.14 Mn by 2031 at a CAGR of 7.80%, from USD 488.44 Mn in 2021.

Market.US announces the publication of a recently generated research report titled, “Global Interventional Oncology Ablation Market, by Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation) by Indication (Liver Cancer, Kidney Cancer, Lung Cancer, Other Indications), By End-Use (Hospitals, Ambulatory Surgical Centers, Other End-Uses), and by Region – Global Forecast to 2031”. This report offers a holistic view of the global Interventional oncology ablation market through systematic segmentation that covers every aspect of this target market.

Ablation can be used as a standalone or in combination with other treatments. Ablation can be performed using various methods, including radiofrequency, microwave, and laser ablation. Interventional oncology ablation is a minimally invasive technique used to treat cancer. The procedure uses high-energy radiation or heat to destroy cancer cells. Ablation can be used to treat a variety of cancers, including liver, lung, and pancreatic cancers. The procedure is typically performed using image guidance tools such as ultrasound or CT scans. Interventional oncology ablation is a treatment that uses heat or cold to destroy cancer cells. Ablation can be used to treat cancers that have spread to other parts of the body or those that cannot be removed with surgery. The procedure is done using a probe that is inserted into the tumor.

There are risks associated with any medical procedure. When considering an interventional oncology ablation procedure, it is important to understand the risks and how they may impact an individual’s health. Some of the risks associated with this procedure include bleeding, infection, reaction to the anesthesia, and damage to surrounding tissues. While these risks may seem scary, it is important to remember that they are rare and that a doctor will take steps to minimize them.

Global Interventional Oncology Ablation Market Revenue (US$ Mn), 2021–2031

Source: Prudour, 2021

Tumor ablation treatments have become a safe and painless process, particularly due to excellent results both during and after the procedure, as a consequence of continued research & development. Cancer ablation is becoming a popular cancer therapy method for several forms of cancer, such as liver cancer, kidney cancer, and so on. In a pilot investigation, researchers from the University of Missouri School of Medicine discovered a therapeutic combination in December 2020 that greatly reduced tumor development and extended the lifespan of mice with liver cancer. This discovery could pave the way for a novel therapeutic strategy for one of the world’s leading causes of cancer-related deaths. It’s an integrated therapy that combines the chemotherapeutic medicine Sunitinib with minimally invasive Radiofrequency Ablation (RFA). Developing a successful Sunitinib and RFA combination therapy significantly contributes to the field of liver cancer treatment. It can be promptly translated into practical applications because Sunitinib and RFA are FDA-approved, widely available cancer medicines. Another key element propelling market expansion is the increasing incidence of cancer. According to research issued by the European Cancer Information System in July 2020, the cancer burden in 27 European nations is expected to increase to 2.7 million new cases (excluding non-melanoma skin cancer) and 1.3 million fatalities in 2020. According to the same source, cancer accounted for 62% of estimated new diagnoses and 76% of predicted deaths in adults over 65 in EU nations in 2020. These are certain factors that are anticipated to help augment this market in the years to come.

Patients undergoing oncology ablation techniques like radiofrequency (RFA) and microwave ablation may experience a wide range of side effects. This is anticipated to negatively impact this market, potentially hindering adoption rates over the next decade.

The COVID-19 pandemic impacted nearly every business, including the interventional oncology ablation market. A majority of healthcare organizations redirected their priorities to combat this outbreak, which resulted in some elective procedures and diagnostic treatments being postponed, canceled, or done in limited numbers. Surgeries using interventional oncology ablation, hemostats, or adhesion barriers have dramatically decreased the world, stifling the interventional oncology ablation market’s revenue growth trajectory. With a decrease in surgeries, businesses saw a decline in the demand for sealants. Several patients shied away from operating in contagious areas for fear of serious consequences. Due to a lack of resources and trade barriers, this aspect of the healthcare industry suffered. As a result, this had a negative influence on the market for Interventional Oncology Ablation.

As major market players are focusing on inorganic growth strategies such as acquisitions, partnerships, and agreements to strengthen their respective product portfolios and market presence on the global stage, the interventional oncology ablation market is expected to create lucrative opportunities shortly. For example, in January 2019, Medtronic plc agreed to purchase Epix Therapeutics, which manufactures catheter-based systems to treat patients with atrial fibrillation. The company’s cardiac ablation portfolio will likely grow due to the acquisition. Furthermore, Boston Scientific agreed to buy Criterion Medical in July 2018, a firm that created a single-shot cryoablation platform for treating atrial fibrillation. The former company will be able to provide cryothermal and radiofrequency (RF) single-shot, balloon-based ablation therapies as a result of this agreement.

The Global Interventional Oncology Ablation Market Segmentation is Based on Technology, Indication, End-Use, and Region

Based on Technology

• Radiofrequency Ablation
• Microwave Ablation
• Cryoablation
• Irreversible Electroporation Ablation

Based on Indication

• Liver Cancer
• Kidney Cancer
• Lung Cancer
• Other Indications

Based on End-Use

• Hospitals
• Ambulatory Surgical Centers
• Other End-Uses

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

This research report on the global interventional oncology ablation market includes major company profiles such as

• Boston Scientific Corporation
• Johnson & Johnson
• Medtronic Plc
• Varian Medical Systems Inc.
• EDAP TMS S.A.
• AngioDynamics
• CASCINATION AG
• Merit Medical Systems Inc.
• STARmed Co.
• Biomedical Srl., among others.

For the Interventional Oncology Ablation Market research study, the following years have been considered to estimate the market size: